Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients

Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients

Bruton’s tyrosine kinase inhibitor ibrutinib has significantly changed treatment landscape in chronic lymphocytic leukemia (CLL). Growing evidence supports ibrutinib to work beyond the effect on tumor cells by means of, for example, restoring functionality of the T-cell compartment and increasing ci...

Full description

Bibliographic Details
Main Authors: Tamara Mateu-Albero, Ana Marcos-Jimenez, Stefanie Wissmann, Javier Loscertales, Fernando Terrón, Jens V. Stein, Cecilia Muñoz-Calleja, Carlos Cuesta-Mateos
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
T-cell
CCR7
CLL
ibrutinib
lymph node
migration
Online Access:https://www.mdpi.com/2072-6694/14/11/2729

Similar Items

Similar Items